Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature 449, 24 (6 September 2007) | doi:10.1038/449024c; Published online 5 September 2007
Diverse approaches useful for microbicide trials
Salim S. Abdool Karim1 & Quarraisha Abdool Karim1
- CAPRISA, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
Your News story 'HIV trial doomed by design, say critics' (Nature 448, 110–111; 2007), portrays a biased and excessively pessimistic view of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial. As the first microbicide trial to be initiated from, and partially funded by, South Africa, the CAPRISA 004 trial promises to address some fundamental questions about the safety and effectiveness of tenofovir as a microbicide gel.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South AfricaClinical Pharmacology & Therapeutics Letter
Ten-year review of research in South AfricaNature Correspondence (29 Apr 2004)
Ten-year review of research in South AfricaNature Correspondence (29 Apr 2004)
See all 9 matches for Research